Defence Therapeutics (DTC) AI Stock Analysis

• Market Cap: C$35.00M
• Dividend Yield: N/A
• Average Volume (3M): 68.27K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.61
• Revenue Growth: N/A
• EPS Growth: 72.92%
• Country: CA
• Employees: 5
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.03
• Shares Outstanding: 57,369,970
• 10 Day Avg. Volume: 109,889
• 30 Day Avg. Volume: 68,269
• PEG Ratio: 0.13
• Price to Book (P/B): -27.77
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -10.26
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 45 Neutral
• Price Target: C$0.63 ▼(-18.72% Downside)
• Action: Reiterated Date: 02/23/26
• Date: Action: Reiterated 02/23/26

The score is primarily constrained by very weak financial performance (no revenue, ongoing losses/cash burn, and negative equity). Technicals are mixed with short-term stabilization but longer-term weakness, and valuation provides limited support due to negative earnings and no dividend yield.

Positive Factors

Proprietary Accum™ delivery platform

A proprietary intracellular delivery platform is a durable competitive asset: it can be applied across ADCs, vaccines and biologics, enabling differentiated payload delivery and immune enhancement. This technical moat supports long-term pipeline optionality and potential partner licensing opportunities.

Focus on oncology and infectious disease

Concentrating R&D on oncology and infectious disease aligns the company with structural, high-demand markets where improved delivery and immune activation are prioritized. This sector focus increases long-term commercial potential and relevance of the Accum™ platform across large addressable markets.

Improving reported losses and FCF trend

A material reduction in annual losses and an improvement in free cash flow growth are constructive operating signals. If sustained, these trends point to improved cost discipline and better cash runway dynamics, lowering near-term financing needs and supporting longer-term R&D continuity.

Negative Factors

Zero revenue base

The company reports no revenue and negative gross profit, indicating no commercialization to fund operations. This structural lack of product revenue means continued dependence on capital markets or partnerships to finance R&D, raising execution and dilution risk over the medium term.

Negative shareholders' equity

Negative shareholders' equity signals accumulated losses and dilution that reduce financial flexibility. This structural weakness complicates leverage interpretation, increases refinancing or dilution risk, and can hinder strategic transactions or partner confidence over the coming months.

Sustained negative operating cash flow

Persistent negative operating cash flow (~-4.9M TTM) demonstrates ongoing cash burn and reliance on external funding. Structurally, this constrains near-term investment capacity, increases financing needs, and elevates execution risk if capital access tightens or costs rise.

Defence Therapeutics Business Overview & Revenue Model

Company Description

Defence Therapeutics Inc., a biotechnology company, engages in the research and development of biological/biosimilar therapeutic drugs for cancer and infectious diseases. Its proprietary platform is the ACCUMTM technology, which enables precision delivery of vaccine antigens or ADCs in their intact form to target cells. The company focuses on developing dendritic cell cancer vaccines; protein-based vaccine formulation against COVID and infectious diseases; and antibody drug conjugates (ADC) products targeting various cancers. The company was formerly known as Accum Therapeutics Inc. and changed its name to Defence Therapeutics Inc. in March 2020. Defence Therapeutics Inc. was incorporated in 2017 and is headquartered in Vancouver, Canada.

How the Company Makes Money

Defence Therapeutics generates revenue through the development and commercialization of its proprietary Accum™ technology, which is licensed to pharmaceutical companies and research institutions. The company earns income from licensing agreements, research and development collaborations, and potentially milestone payments and royalties from partners that utilize its technology in their therapeutic development. Additionally, Defence Therapeutics may receive funding from government grants or subsidies for their contribution to advancing healthcare solutions.

Defence Therapeutics Financial Statement Overview

Summary

Very weak fundamentals: zero revenue, persistent losses, and ongoing cash burn. Balance-sheet risk is elevated with negative shareholders’ equity in recent periods, implying continued reliance on external financing despite some improvement in annual losses versus 2024.

Income Statement

Financial performance remains very weak. Across annual periods and TTM (Trailing-Twelve-Months), the company reports zero revenue and consistently negative gross profit, implying ongoing operating spend without commercialization. Losses are sizable, though they improved materially from 2024 (net loss about -13.2M) to 2025 annual (about -3.5M), but TTM (Trailing-Twelve-Months) losses widened again (about -4.3M), highlighting volatility and limited earnings visibility.

Balance Sheet

Balance sheet risk is elevated due to negative shareholders’ equity in the most recent periods (2024 onward), which reduces financial flexibility and makes leverage harder to interpret (debt-to-equity turns negative). Total debt is meaningful (~1.5M in 2025) while assets remain modest (about 1.4M in TTM). A key positive is that equity was positive in 2023 (about 1.6M), but the subsequent swing into negative equity signals dilution, accumulated losses, and/or balance-sheet pressure.

Cash Flow

Cash generation is weak with consistently negative operating cash flow and negative free cash flow each period, indicating ongoing cash burn typical of early-stage biotech. Losses were reduced versus 2024, but TTM (Trailing-Twelve-Months) operating cash flow is still heavily negative (about -4.9M). A modest positive is that free cash flow improved versus the prior comparable period (TTM free cash flow growth is positive), but the business still relies on external funding until revenue and cash flow turn sustainably positive.

Breakdown	TTM	Sep 2025	Jun 2024	Sep 2023	Sep 2022	Sep 2021
Income Statement
Total Revenue	0.00	0.00	0.00	0.00	0.00	0.00
Gross Profit	-44.73K	-72.34K	-90.92K	-13.82K	0.00	0.00
EBITDA	-3.98M	-3.13M	-12.68M	-6.48M	0.00	0.00
Net Income	-4.33M	-3.52M	-13.19M	-6.76M	-7.34M	-2.86M
Balance Sheet
Total Assets	1.37M	1.65M	477.75K	3.53M	719.67K	5.61M
Cash, Cash Equivalents and Short-Term Investments	947.35K	1.23M	56.55K	2.79M	506.70K	5.45M
Total Debt	1.49M	1.50M	1.75M	1.75M	0.00	0.00
Total Liabilities	2.59M	2.91M	4.06M	1.97M	1.11M	122.26K
Stockholders Equity	-1.22M	-1.26M	-3.58M	1.57M	-387.56K	5.49M
Cash Flow
Free Cash Flow	-4.13M	-3.40M	-4.49M	-7.72M	-6.04M	-2.29M
Operating Cash Flow	-4.94M	-3.40M	-4.29M	-7.66M	-6.04M	-2.29M
Investing Cash Flow	-30.05K	3.60K	-203.24K	-65.80K	0.00	0.00
Financing Cash Flow	5.79M	4.57M	1.76M	10.01M	1.10M	5.88M

Defence Therapeutics Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 0.78
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:DTC, the sentiment is Neutral. The current price of 0.78 is above the 20-day moving average (MA) of 0.61, above the 50-day MA of 0.64, and above the 200-day MA of 0.72, indicating a neutral trend. The MACD of >-0.01 indicates Negative momentum. The RSI at 52.04 is Neutral, neither overbought nor oversold. The STOCH value of 38.89 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for TSE:DTC.

Defence Therapeutics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
APS	51 Neutral	C$5.59M	-0.15	―	―	―	90.81%
DTC	45 Neutral	C$35.00M	-6.55	―	―	―	72.92%
BCT	44 Neutral	C$39.88M	-0.63	-409.25%	―	―	62.01%
MDNA	42 Neutral	C$59.79M	-4.40	-91.21%	―	―	54.74%
BIOV	29 Underperform	$3.50M	-1.60	―	―	―	25.09%

Defence Therapeutics Corporate Events

Defence Therapeutics Refines Accum ADC Strategy with Expert Advisory Board

Defence Therapeutics has convened its Scientific Advisory Board to refine the strategic development of its Accum® platform for antibody-drug conjugate applications. The meeting brought together experts in ADC chemistry, translational science, and value creation to align scientific priorities with clinical and partnering requirements.

Insights from advisors with experience at AbbVie, Zymeworks, Abdera Therapeutics, and Kairos Therapeutics are guiding the next phase of Accum® development. As a result, Defence is updating its ADC roadmap to better match platform capabilities with clinical needs and partnership expectations, reinforcing Accum®’s positioning as a next-generation intracellular delivery technology.

The company aims for Accum®-enabled ADCs to deliver more effective and better-tolerated cancer therapies by improving intracellular payload delivery at potentially lower doses. This strategic alignment is intended to support Defence’s push toward clinical translation and to enhance its attractiveness to pharmaceutical and biotech partners seeking differentiated ADC platforms.

The most recent analyst rating on (TSE:DTC) stock is a Hold with a C$0.60 price target. To see the full list of analyst forecasts on Defence Therapeutics stock, see the TSE:DTC Stock Forecast page.

Defence Therapeutics Refines Accum ADC Strategy With New Scientific Advisory Board

Defence Therapeutics has convened a multidisciplinary Scientific Advisory Board to refine the strategic development of its Accum® platform for antibody-drug conjugate applications, emphasizing improved intracellular delivery of ADC payloads. The board’s experts in ADC chemistry, translational science, and value creation are helping the company prioritize key scientific questions, optimize study design, and align data generation with the expectations of future clinical and pharmaceutical partners.

Insights from advisors with experience at AbbVie, Zymeworks, Abdera Therapeutics, Kairos Therapeutics, and in capital formation are shaping the next phase of Accum® development as it moves toward clinical translation and strategic collaborations. By recalibrating its ADC roadmap to better match clinical requirements and partnering considerations, Defence aims to position Accum® as a next-generation intracellular delivery solution that could enable more effective and better-tolerated ADC therapies, potentially strengthening its standing in the oncology drug-delivery space.

The most recent analyst rating on (TSE:DTC) stock is a Hold with a C$0.60 price target. To see the full list of analyst forecasts on Defence Therapeutics stock, see the TSE:DTC Stock Forecast page.

Defence Therapeutics to Spotlight Accum Platform at World ADC Europe 2026

Defence Therapeutics will present its Accum platform at World ADC Europe 2026 in London, positioning the technology as a means to enhance intracellular delivery for antibody-drug conjugates and advanced oncology biologics. By engaging prospective pharma and biotech partners at this forum, the company seeks to expand collaborations that could accelerate Accum-enabled therapeutics and reinforce its standing in precision oncology.

The most recent analyst rating on (TSE:DTC) stock is a Hold with a C$0.60 price target. To see the full list of analyst forecasts on Defence Therapeutics stock, see the TSE:DTC Stock Forecast page.

Defence Therapeutics Deepens CNL Partnership to Fast-Track Radiopharmaceutical Pipeline

Defence Therapeutics has expanded its long-standing collaboration with Canadian Nuclear Laboratories to accelerate development of its Accum®-enhanced radiopharmaceutical pipeline. Building on progress in a lead radio-immunoconjugate program that is nearing candidate selection and preparation for first-in-human clinical studies, the partners will now initiate multiple additional radioisotope programs using Defence’s intracellular delivery technology. The move elevates radiopharmaceuticals to one of Defence’s top development priorities alongside its ADC program, strengthens its position in targeted cancer therapies, and is intended to speed the translation of its proprietary platform into the clinic, with potential implications for more potent, less toxic first-line cancer treatments.

The most recent analyst rating on (TSE:DTC) stock is a Hold with a C$0.60 price target. To see the full list of analyst forecasts on Defence Therapeutics stock, see the TSE:DTC Stock Forecast page.

Defence Therapeutics Refines Strategy Around Accum® Precision Drug-Delivery Platform

Defence Therapeutics has refined its corporate positioning to emphasize its role as a precision intracellular drug-delivery specialist centered on its proprietary Accum® platform. By improving cellular uptake and payload release, Accum® is designed to boost the effectiveness of complex cancer biologics at lower doses, potentially reducing toxicity and enabling certain therapies traditionally reserved for later treatment lines to be used earlier in care. The company is pursuing a dual strategy of advancing its own R&D programs while expanding strategic partnerships across the biotech and pharmaceutical ecosystem, with the aim of creating scalable value for partners and strengthening its position in precision oncology while seeking to deliver better outcomes for patients and long-term value for shareholders.

The most recent analyst rating on (TSE:DTC) stock is a Hold with a C$0.58 price target. To see the full list of analyst forecasts on Defence Therapeutics stock, see the TSE:DTC Stock Forecast page.

Defence Therapeutics Announces AGM Results and Strategic Updates

Defence Therapeutics announced the successful approval of all matters at its annual general meeting, including the election of directors and the appointment of auditors. The company has granted 800,000 stock options and amended the terms of 967,000 common share purchase warrants, extending their expiry date and adjusting the exercise price. Additionally, Defence has engaged i2i Marketing Group for a two-month online marketing campaign to enhance its market presence.

Defence Therapeutics Forms Scientific Advisory Board to Propel ADC Programs

Defence Therapeutics has announced the formation of its inaugural Scientific Advisory Board (SAB) to guide the advancement of its Accum-enhanced Antibody Drug Conjugate (ADC) programs. The SAB, comprising experts in antibody-based therapeutics and biotechnology, will provide strategic guidance as the company progresses its Accum-enabled ADC programs from preclinical development towards clinical applications. This move is expected to strengthen Defence’s scientific foundation and support its long-term development strategy, potentially enhancing its position in the biotechnology industry.